Key facts
- LambdaVision’s last known valuation is $4.8M (Sep 2017).
- It has raised $9.2M; the latest was Seed Round ($7.0M) in Nov 2025.
- Notable investors include US National Science Foundation, MassChallenge, Connecticut Innovations, VentureWell, Seraphim Space — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for LambdaVision
- ·The full record, as it builds
Funding rounds
No funding rounds for LambdaVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LambdaVision
Developer of a retinal implant technology designed to restore meaningful vision for patients blinded by retinal degenerative diseases. The company's technology utilizes a light-activated protein, bacteriorhodopsin, to stimulate the retinas of patients with impaired vision or sight loss due to retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, enabling health providers to enhance the quality of life for those afflicted by retinal degeneration.
- Sector
- Healthcare
- HQ
- Woodbridge, CT, United States
- Founded
- 2009
- Employees
- 9
- Website
- lambdavision.com/
- Ownership
- Privately Held (backing)
LambdaVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LambdaVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LambdaVision in its N-PORT filings yet. We sweep new filings monthly.